GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC

Author： Liang Kung-Hao   Lin Chen-Chun   Yeh Chau-Ting  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.12, Iss.7, 2011-07, pp. : 1061-1073

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Treatment of Borrmann Type IV Gastric Cancer with a Neoadjuvant Chemotherapy Combination of Docetaxel, Cisplatin and 5-Fluorouracil/Leucovorin

By Sun X-C   Lin J   Ju A-H  

The Journal of International Medical Research, Vol. 39, Iss. 6, 2011-11 ,pp. : 2096-2102

Field House Publishing

Access to resources Recommend Favorite

Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy

By Zhang Xue   Diasio Robert B  

Pharmacogenomics, Vol. 8, Iss. 3, 2007-03 ,pp. : 257-265

Future Medicine

Access to resources Recommend Favorite

Paclitaxel in combination with cisplatin is "active and promising" in advanced squamous cell oesophageal cancer

By  

Inpharma, Vol. 1, Iss. 1629, 2008-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

A Novel Combination of Cisplatin, Irinotecan, and Capecitabine in Patients with Advanced Cancer

By Jefford Michael   Michael Michael   Rosenthal Mark A.   Davis Ian D.   Green Michael   McClure Bev   Smith Jennifer   Waite Brigid   Zalcberg John  

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 185-192

Springer Publishing Company

Access to resources Recommend Favorite

The combination of cisplatin, epirubicin and vinorelbine effectively treats advanced breast cancer

By  

Inpharma, Vol. 1, Iss. 1428, 2004-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite